India’s Perfint Develops Tools to Assist in Tumor Ablation

Chennai, India-based Perfint Healthcare, has developed MAXIO, an image-guided, physician controlled robotic system that assists physicians to visualize and plan an entire procedure such as tumor ablation in 3D. Once the plan is confirmed, MAXIO’s stereotactic arm, combined with intra-operative registration, assists surgeons  to advance one or more instruments accurately to reach the target.

Founders S. Nandakumar, K. Guruswamy, K. Puhazhendi and Gopalakrishna Kulkarni spent a decade at  GE Healthcare prior to creating this company. After talking to a number of radiologists and physicians in India, the team designed a product that  is useful in treating tumors and managing pain rather than just diagnosing the tumor.

MAXIO

Maxio, an FDA 510k approved device is used  in the  U.S., Germany, Australia and India. . “It’s the best money can buy in two important areas of medical technology. There are similar systems that only the first world can afford, but this one is world-class, cost-effective and for me, this is true advancement in medicine,” says, Dr Yuman Fong, chair of surgery at City of Hope, the cancer research hospital in Duarte, California,  reports Outlook Business.

Be Sociable, Share!
Posted on by Gunjan Bagla
Gunjan Bagla
California-based management consultant Gunjan Bagla runs Amritt, a consulting firm helping American companies to succeed in India. Amritt is the trusted advisor for India market research, India business development, India market entry, Global Engineering, Global Technology Scouting, India R&D and Open Innovation. Gunjan is author of "Business in 21st Century India: How to Profit Today from Tomorrow’s Most Exciting Market" (Hachette Book Group, 2008), Amazon's top rated title on the subject. He has appeared as the India Expert on BBC Television, Bloomberg TV, Fox Cable Business and has been quoted in the New York Times, the Los Angeles Times, the Hollywood Reporter and Business Week for his expertise on India.

0 comments

There are no comments yet...

Kick things off by filling out the form below.

Leave a Comment

*